Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Updates in Surgery
Published in: Updates in Surgery 2/2021

01-04-2021 | Liver Resection | Original Article

Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival

Authors: Yueh-Wei Liu, Chee-Chien Yong, Chih-Che Lin, Chih-Chi Wang, Chao-Long Chen, Yu-Fan Cheng, Jing-Houng Wang, Yi-Hao Yen

Published in: Updates in Surgery | Issue 2/2021

Login to get access

Abstract

To determine the optimal cutoff time point of early versus late recurrence relative to post-recurrence survival (PRS) among patients who underwent liver resection (LR) for hepatocellular carcinoma (HCC) in a high-volume liver surgery center in East Asia. This was a retrospective study. Patients who underwent LR for HCC between 2011 and 2018 at Kaohsiung Chang Gung Memorial Hospital were enrolled. The optimal cutoff time point to differentiate early versus late recurrence was evaluated relative to PRS. Among 826 patients, 282 (34.1%) of the patients experienced recurrence, with a median time to recurrence of 12.2 months. 6 months was defined as the optimal cutoff time point based on sensitivity analyses relative to PRS. Ninety (31.9%) of the patients developed early recurrence within 6 months, and 192 patients (68.1%) developed late recurrence beyond 6 months. Early recurrence was associated with worse PRS (median PRS, 13.2 versus 48.9 months, p < 0.001), as well as overall survival (OS) (median OS, 16.2 versus 65.4 months, p < 0.001), than late recurrence. Six months was identified as the cutoff time point to differentiate early versus late recurrence among patients undergoing LR for HCC.
Literature
1.
EASL Clinical Practice Guidelines (2018) Management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef
2.
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed
3.
Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422CrossRefPubMed
4.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
5.
Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRefPubMed
6.
Ding X, He M, Chan AWH et al (2019) Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157:1630-1645.e1636CrossRefPubMed
7.
Tabrizian P, Jibara G, Shrager B et al (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955CrossRefPubMed
8.
Groot VP, Gemenetzis G, Blair AB et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162CrossRefPubMed
9.
10.
Xing H, Zhang WG, Cescon M et al (2020) Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxf) 22:677–689CrossRef
11.
American Joint Committee on Cancer (2010) American Joint Committee on Cancer Staging Manual, 7th ed. In: Edge SB, Byrd DR, Compton CC et al (eds). Springer, New York, p 175
12.
Abou-Alfa GK, Pawlik TM, Shindoh J et al (2017) Liver. In: AJCC cancer staging manual, 8th ed, Amin MB (Ed), AJCC, Chicago, p 287
13.
Edmonson H, Steiner P (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef
14.
Everhart JE, Wright EC, Goodman ZD et al (2010) Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51:585–594CrossRefPubMed
15.
Benson AB, Abrams TA, Ben-Josef E et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391CrossRefPubMedPubMedCentral
16.
Kokudo N, Hasegawa K, Akahane M et al (2015) Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update 3rd JSH-HCC Guidelines. Hepatol Res 45:2CrossRef
17.
Kudo M, Matsui O, Izumi N et al (2014) Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral
18.
Kudo M, Izumi N, Kokudo N et al (2011) HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed
19.
Omata M, Lesmana LA, Tateishi R et al (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474CrossRefPubMedPubMedCentral
20.
Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMed
21.
Meniconi RL, Komatsu S, Perdigao F et al (2015) Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 157:454–462CrossRefPubMed
22.
Shindoh J, Kawamura Y, Kobayashi Y et al (2020) Time-to-interventional failure as a new surrogate measure for survival outcomes after resection of hepatocellular carcinoma. J Gastrointest Surg 24:50–57CrossRefPubMed
23.
Van Deusen MA, Abdalla EK, Vauthey JN et al (2005) Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 5:377–383CrossRefPubMed
24.
Torzilli G, Donadon M, Belghiti J et al (2016) Predicting individual survival after hepatectomy for hepatocellular carcinoma: a novel nomogram from the “HCC East & West Study Group.” J Gastrointest Surg 20:1154–1162CrossRefPubMed
25.
Galle PR, Foerster F, Kudo M et al (2019) Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019(39):2214–2229CrossRef
26.
Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16:792–794CrossRefPubMed
27.
Yamamoto Y, Ikoma H, Morimura R et al (2015) Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol 21:1207–1215CrossRefPubMedPubMedCentral
28.
Toyoda H, Lai PB, O’Beirne J et al (2016) Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 114:744–750CrossRefPubMedPubMedCentral
29.
Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558CrossRefPubMed
30.
Chan AWH, Zhong J, Berhane S et al (2018) Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 69:1284–1293CrossRefPubMed
31.
Lee YC, Cohet C, Yang YC, Stayner L et al (2009) Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 38:1497–1511CrossRefPubMed
32.
Shen YC, Hsu C, Chen LT et al (2010) Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 52:889–894CrossRefPubMed
33.
Wong JS, Wong GL, Tsoi KK et al (2011) Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33:1104–1112CrossRefPubMed
34.
Poon RT, Fan ST, Lo CM et al (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235:373–382CrossRefPubMedPubMedCentral
35.
Sandri GBL, Ettorre GM, Aldrighetti L et al (2019) Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 33:1451–1458CrossRef
36.
Levi GB, Sandri QL, Ravaioli M et al (2020) The role of salvage transplantation in patients initially treated with open versus minimally invasive liver surgery: an intention-to-treat analysis. Liver Transpl 26:878–887CrossRef
Metadata
Title
Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival
Authors
Yueh-Wei Liu
Chee-Chien Yong
Chih-Che Lin
Chih-Chi Wang
Chao-Long Chen
Yu-Fan Cheng
Jing-Houng Wang
Yi-Hao Yen
Publication date
01-04-2021
Publisher
Springer International Publishing
Published in
Updates in Surgery / Issue 2/2021
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-020-00931-2

Other articles of this Issue 2/2021

Updates in Surgery 2/2021 Go to the issue

Original Article

Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis?

Original Article

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients

Original Article

The rise of one anastomosis gastric bypass: insights from surgeons and dietitians

Original Article

Intraoperative neuromonitoring during prone thoracoscopic esophagectomy for esophageal cancer reduces the incidence of recurrent laryngeal nerve palsy: a single-center study

Original Article

Factors associated with prolonged hospital stay after laparoscopic adrenalectomy

Original Article

Effectiveness of endoscopic vacuum therapy as rescue treatment in refractory leaks after gastro-esophageal surgery